The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2025 | Early results from EVEREST-2 of A2B694, a CAR T therapy, in solid tumors
Salman Punekar, MD, NYU Langone, New York, NY, discusses initial findings from the Phase I/II EVEREST-2 trial (NCT06051695) of A2B694, a logic-gated Tmod CAR T therapy targeting mesothelin-expressing tumors with HLA-A*02 loss of heterozygosity. Patients with advanced cancers received A2B694 following lymphodepletion. Early data show manageable safety with no dose-limiting toxicities or cytokine release syndrome, with a partial response observed in one patient with non-small cell lung cancer (NSCLC). This interview took place at 2025 World Conference on Lung Cancer (WCLC) in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Yeah, the EVEREST-2 trial is an innovative concept. So it utilizes a CAR T cell that has a dual approach, has an activating CAR against mesothelin, has a blocking CAR against HLA. And this Everest 2 trial is a phase one dose escalation trial. And today we’re presenting some efficacy data. We’re really excited to present a KRAS STK11 mutated patient who had a PR at three months...
Yeah, the EVEREST-2 trial is an innovative concept. So it utilizes a CAR T cell that has a dual approach, has an activating CAR against mesothelin, has a blocking CAR against HLA. And this Everest 2 trial is a phase one dose escalation trial. And today we’re presenting some efficacy data. We’re really excited to present a KRAS STK11 mutated patient who had a PR at three months. and we’ll be presenting further data at an upcoming congress.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
